1-4 of 4
Chandtip Chandhasin
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract A050: A Phase 1 dose escalation study of TACH101, a first-in-class KDM4 inhibitor for advanced solid tumors

Apostolia Tsimberidou, Andrae L Vandross, David Sommerhalder, Charmaine Joseph, Chandtip Chandhasin, Frank Perabo, Michael F Clarke
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2023) 22 (12_Supplement): A050.
https://doi.org/10.1158/1535-7163.TARG-23-A050
Published: 01 December 2023
View article titled, Abstract A050: A Phase 1 dose escalation study of TACH101, a first-in-class KDM4 inhibitor for advanced solid tumors
Journal Articles

Abstract P086: Identification of pharmacodynamic and sensitivity biomarkers for TACH101, a pan-inhibitor of KDM4 histone lysine demethylase

Frank Perabo, Sanghee Yoo, Chandtip Chandhasin, Joselyn Del Rosario, Young K. Chen, Ellen Filvaroff, Jeffrey A. Stafford, Stephen Quake, Michael F. Clarke
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2021) 20 (12_Supplement): P086.
https://doi.org/10.1158/1535-7163.TARG-21-P086
Published: 01 December 2021
View article titled, Abstract P086: Identification of pharmacodynamic and sensitivity biomarkers for TACH101, a pan-inhibitor of KDM4 histone lysine demethylase
Journal Articles

Safety, Pharmacokinetics, and Activity of GRN1005, a Novel Conjugate of Angiopep-2, a Peptide Facilitating Brain Penetration, and Paclitaxel, in Patients with Advanced Solid Tumors

Razelle Kurzrock, Nash Gabrail, Chandtip Chandhasin, Stacy Moulder, Carrie Smith, Andrew Brenner, Kamalesh Sankhala, Alain Mita, Kelly Elian, Danielle Bouchard, John Sarantopoulos
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2012) 11 (2): 308–316.
https://doi.org/10.1158/1535-7163.MCT-11-0566
Published: 08 February 2012
View article titled, Safety, Pharmacokinetics, and Activity of GRN1005, a Novel Conjugate of Angiopep-2, a Peptide Facilitating Brain Penetration, and Paclitaxel, in Patients with Advanced Solid Tumors
Open the PDF for Safety, Pharmacokinetics, and Activity of GRN1005, a Novel Conjugate of Angiopep-2, a Peptide Facilitating Brain Penetration, and Paclitaxel, in Patients with Advanced Solid Tumors in another window
Journal Articles

Phase I dose escalation study of sodium stibogluconate (SSG), a protein tyrosine phosphatase inhibitor, in combination with interferon-α for patients with solid tumors

Luis Camacho, Aung Naing, Claire Verschraegen, Funda Meric-Bernstam, David Hong, Stacy Moulder, Cataliner Gutierrez, Saneese Stephen, Chandtip Chandhasin, Hui Gao, Evans Cohen, Bang-Ning Lee, Maritza Martinez, Lawrence Akinsanmi, Razelle Kurzrock, James Reuben
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2007) 6 (11_Supplement): B89.
Published: 01 November 2007
View article titled, Phase I dose escalation study of sodium stibogluconate (SSG), a protein tyrosine phosphatase inhibitor, in combination with interferon-α for patients with solid tumors